Completed PHASE2 INTERVENTIONAL 4-arm NCT00762073

Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis

Oral Viscous Budesonide Suspension (MB-7) in Subjects With Eosinophilic Esophagitis: A Randomized, Placebo-Controlled, Dose-Ranging Study in Children and Adolescents

Sponsor: Shire

Conditions Eosinophilic Esophagitis (EoE)

Interventions budesonide placebo

Updated 7 times since 2017 Last updated: Jun 4, 2021 Started: Jan 8, 2009 Primary completion: Apr 2, 2010 Completion: Apr 2, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Eosinophilic Esophagitis (EoE), this trial is completed. The trial is conducted by Shire and has accumulated 7 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Sep 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Sep 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shire

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Aurora, United States , Boston, United States , Chicago, United States , Greenville, United States , Indianapolis, United States , Las Vegas, United States , Mays Landing, United States , Norfolk, United States , Omaha, United States and 8 more locations